Prime Medicine, Inc. PRME
Prime Medicine, Inc. (Nasdaq: PRME) is a rare genetic drug developer. Its lead program, PM577a, is in Phase 1 for Wilson disease. Its next catalyst on record is PM359: BLA submission (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PM359 — BLA submission (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PM577a | Wilson disease | gene therapy | Phase 1 |
| PM359 | Chronic Granulomatous Disease (CGD) | cell therapy | Phase 1 |
| PM647 | AATD (Alpha-1 Antitrypsin Deficiency) | gene therapy | Pre-clinical |
| Cystic Fibrosis program | Cystic Fibrosis | gene therapy | Pre-clinical |
Recent results and decisions
- Aug 6, 2026started Prime Medicine initiated study startup activities for global Phase 1/2 trial of PM577a in Wilson disease following IND and CTA clearances.
Together, the two clearances establish a global Phase 1/2 program. The open-label, first-in-human study will evaluate the safety, tolerability, biological activity and efficacy of ascending doses of PM577a in adults and adolescents with WD, initially enrolling adults who are clinically stable on sta
Filing - Jul 1, 2026accepted FDA cleared IND application for PM577a in Wilson disease in July 2026.
In July 2026, the FDA cleared the Company's IND application for PM577a, opening participation to patients in the United States, where the ATP7B H1069Q variant that PM577a targets is the single most common cause of WD.
Filing - Jul 1, 2026positive Favorable arbitration resolution with Beam Therapeutics affirms Prime Medicine's rights to PM647 in AATD.
The Tribunal declared that PM647 is within Prime Medicine's 'Field' as defined by the agreement, that Prime Medicine did not breach the agreement, and that Prime Medicine owes no monetary damages.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.